MRTNZ

MRTNZ Investment Office · S&P 500 · The 360 Vantage

BMY · NYSE

Bristol-Myers Squibb Company

Health Care · Biotechnology: Pharmaceutical Preparations

Reference price$63.60As of Jul 28, 2026
Market capitalization$130B
52-week range$42.52–$63.44
S&P 500 portfolio weight0.20%
Data qualitycomplete

Street view

Analyst targets

Published sell-side aggregation—not an MRTNZ forecast.

Low$40.00-37.1% vs. reference
Average$63.31-0.5% vs. reference
High$75.00+17.9% vs. reference
6 Buy8 Hold1 Sell

Forward calendar

Current earnings expectations

Consensus may change until the company reports.

Expected reportJul 30, 2026Jun 2026
Consensus EPS$1.598 estimates
Expected range$1.53–$1.61Low to high EPS
Dec 2026$6.34Street EPS consensus
Dec 2027$6.12Street EPS consensus
Dec 2028$5.12Street EPS consensus

Reported results

Annual financial snapshot

Fiscal period ended Dec 31, 2025.

MetricCurrentPrior
Revenue-0.2% YoY$48.19B$48.3B
Operating income$10B($7.49B)
Net income$7.05B($8.95B)
Operating cash flow$14.16B$15.19B
Capital expenditures($1.31B)($1.25B)

Current context

Related news

Company-linked articles surfaced by Nasdaq.

The Motley Fool

This Healthcare Leader Just Made a Bet on Artificial Intelligence (AI): Time to Buy the Stock?

Zacks

Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates?

Zacks

Will REGN's Q2 Earnings Get a Boost From Dupixent and Eylea HD?

Evidence

Sources & method

Nasdaq quote →Nasdaq summary →Earnings forecast →Annual financials →Official S&P 500-tracking holdings →

Facts, estimates, and scenarios are kept separate. Analyst targets and EPS expectations are third-party estimates, not MRTNZ forecasts. Index weight uses the official IVV portfolio as the denominator. Illustrative research, not investment advice.